•  
  • Our History
  • Product History
  • Certifications
•  
  • Technical Bulletins & Documents
  • Respiratory Links
•  
  • Oxyview®
    • About Oxyview®
    • Purchase Oxyview®
    • Specifications
    • Instructions For Use
    • Reimbursement Codes
    • Testimonials
    • Video Presentation
    • Manufacturing Oxyview®
    • Brochure
  • PogaMoonga
    • About PogaMoonga
    • Purchase PogaMoonga
•  
  • Distributor Locations
  • Group Purchasing Organizations
  • OEM Partners
•  
  • Contact Information
  • Customer Feedback
  • Distributor Inquiry
•  
  • Corporate Compliance Program
  • Privacy Policy
  • Investor Relations
    • Letter From The Chairman
    • Management
    • Board Of Directors
    • SEC Filings
    • Stock Quotes & Press Releases
    • Investor FAQ
    • Investor Inquiry
    • Corporate Governance

INGEN TECHNOLOGIES, INC.
 -Oxyview® Receives Green-Light from DHS-
-Oxyview® to be distributed by worlds largest supplier-
 

 For Release Wednesday, July 11, 2007 at 8:15 AM (EST)

Yucaipa, California – July 11, 2007 -- Ingen Technologies, Inc. (OTC:ITEC), a medical device manufacturer, announced today that the Department of Health Services has audited the company records and files, and has approved and certified the company to distribute Oxyview® in the USA.

“The Department of Health Services audited our records and files on June 21st  as a routine part of complying with DHS requirements. The company is officially certified with DHS for the manufacture of Oxyview®. We are finalizing ISO requirements for sales outside the US.” Said Chris Wirth, COO.

More important, the Company has completed negotiations with InvaCare Supply Group, Inc., the subsidiary of InvaCare, Inc., a NYSE listed company under symbols “IVC”. A formal announcement of the exclusive distribution agreement will be released next week.

“After several months of negotiations we were able to finalize an Agreement with the InvaCare Supply Group. They have expressed their excitement and confidence in placing OxyView® with their distribution. This changes the playing field for Ingen as we prepare to move to the OTCBB.” Said Scott Sand, CEO & Chairman.

Invacare Corporation is the world's leading manufacturer and distributor in the $8.0 billion worldwide market for medical equipment used in the home. The company designs, manufactures, and distributes an extensive line of health care products for the non-acute care environment, including the home health care, retail, and extended care markets. Today, Invacare has reached approximately $1.5 billion in net sales and is the leading company in each of the following major, non-acute, medical equipment categories: power and manual wheelchairs, home care bed systems, and home oxygen systems. The company sells its products to over 25,000 home health care and medical equipment providers, distributors, and government locations in the United States, Australia, Canada, Europe, New Zealand, and Asia. The company has 5,700 associates and markets its products in 80 countries around the world.  

“This is a major development for our shareholders. InvaCare Supply Group has also requested right of first refusal for the next Ingen product referred to as OxyAlert®.” Said Thomas Neavitt, CFO.

About Ingen Technologies, Inc.

Ingen has devised a business model with some very appealing operational and economic aspects.  First, its core strength is obtaining intellectual property rights (owning patents and trademarks) to technologically advanced products, particularly with medical applications for the elderly portion of the population.  There, aging increases the incidence of balance and breathing disorders.  Second, Ingen out-sources its manufacturing, deliberately avoiding the necessary investment in, and headaches of, manufacturing.  Third, in the case of Secure Balance®, OxyView® and OxyAlert®, the sales function is, and will be, outsourced to organizations with existing marketing channels (and Rolodexes).  Again, Ingen escapes something many companies do not – the costly and time-consuming necessity to create an internal sales force.  There is a rational quid pro quo: Ingen gains immediate access to a productive marketing organization; the latter gains equally rapid access to an additional, and attractive, product to pour through its distribution pipeline.  Thus, there are mutual – and major – economic efficiencies and timesaving, for both parties.

There is a real economic savvy to Ingen’s approach in two particular respects.  First, overhead expenses are sliced to a minimum: no internal manufacturing or selling.  Therefore, a big chunk of any future incremental revenue growth would flow through the income statement to earnings.  Second, in the future, Ingen is positioned to add other interesting technologies to its product portfolio, thereby boosting potential revenues and leveraging earnings.